Compare WHF & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WHF | ADCT |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 136.1M |
| IPO Year | 2012 | 2019 |
| Metric | WHF | ADCT |
|---|---|---|
| Price | $7.91 | $1.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $7.83 | $3.33 |
| AVG Volume (30 Days) | 92.6K | ★ 1.5M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | ★ 31.91 | 30.86 |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.38 | $25.32 |
| P/E Ratio | $18.09 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $6.07 | $0.78 |
| 52 Week High | $8.05 | $4.98 |
| Indicator | WHF | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 70.37 | 52.95 |
| Support Level | $6.91 | $0.97 |
| Resistance Level | N/A | $1.87 |
| Average True Range (ATR) | 0.23 | 0.18 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 91.87 | 40.30 |
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).